Dataset from A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy

This is a multicenter, open-label, 4-arm, randomized, parallel-group study to evaluate safety
and tolerability of Brivaracetam Intravenous (BRV iv) as adjunctive treatment for adults with
epilepsy according to an initiation or a conversion scheme, during repeated dosing (100
mg/administration twice daily for 4.5 days).